# US 2025/0145965 A1 · Production method for induced pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145965 A1
- Document ID: US20250145965A1
- Status: Published application
- Kind: A1
- Application number: 18/835,550
- Filed: 2023-02-02
- Published: 2025-05-08
- Earliest claimed: 2022-02-04
- Assignees: Riken; Kaneka Corporation
- Applicants: Riken; Kaneka Corporation
- Inventors: Yohei HAYASHI; Mami TAKASAKI; Sho KAMBAYASHI; Yoshikazu KAWAI
- Web page: https://patentgrep.com/patent/US20250145965A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 1/00: Microorganisms; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N 5/06: {Animal cells or tissues; Human cells or tissues (preservation of excised living parts A01N1/10)}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/86: Viral vectors
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/1307: from adult fibroblasts
- C12N 2510/00: Genetically modified cells
- C12N 2760/18843: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

To provide a method for producing induced pluripotent stem cells (iPS cells) that can initialize somatic cells without using feeder cells or a substrate. For production of iPS cells, the following steps are carried out: I. introducing an initialization gene into a somatic cell; and II. performing initialization and amplification culture of the cell into which the gene has been introduced, in a liquid medium comprising at least one of a protein kinase Cβ (PKCβ) inhibitor and a WNT inhibitor under a suspension culture condition.

## Claims

### Claim 1

A method for producing an induced pluripotent stem cell (iPS cell), comprising the following steps I and II:
I. introducing an initialization gene into a somatic cell; and
II. performing initialization and amplification culture of the cell into which the gene has been introduced, in a liquid medium comprising at least one selected from the group consisting of a protein kinase Cβ (PKCβ) inhibitor and a WNT inhibitor under a suspension culture condition.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising the following steps III and IV:
III. sorting an undifferentiation marker positive cell from the cell obtained in the step II; and
IV. performing suspension culture of the undifferentiation marker positive cell sorted in the step III to obtain a cell population.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the step III is a step of fractionating the sorted cell.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the undifferentiation marker is at least one selected from the group consisting of SSEA-4, TRA-1-60, TRA-1-81 and TRA-2-49.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the somatic cell is a blood mononuclear cell.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the gene to be introduced into the somatic cell is incorporated into an episomal plasmid or Sendai virus and introduced into the somatic cell.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the initialization gene to be introduced comprises at least one gene selected from the group consisting of an OCT3/4 gene, a KLF4 gene and an L-MYC gene.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the liquid medium used in and after the step II comprises at least one selected from L-ascorbic acid, insulin, transferrin, selenium and sodium hydrogen carbonate.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the liquid medium used in and after the step II comprises FGF2 and/or TGF-β1.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the liquid medium used in and after the step II comprises a ROCK inhibitor.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the ROCK inhibitor is Y-27632.

### Claim 12 (depends on 2)

The method according to claim 2, wherein, in the cell population obtained in the step IV, the proportion of cells positive for OCT4 is 90% or higher, and the proportion of cells positive for NANOG in the obtained cell population is 90% or higher.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the step II comprises a procedure of colleting a cell aggregate.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the step IV comprises a procedure of collecting a cell aggregate.

### Claim 15 (depends on 1)

A cell population comprising iPS cells produced by the method according to claim 1.

### Claim at position 16

16-23. (canceled)
